Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer

BACKGROUND AND OBJECTIVE: Several clinical trials have proven that icotinib hydrochloride, a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Shen, Yan-Wei, Zhang, Xiao-Man, Li, Shu-Ting, Lv, Meng, Yang, Jiao, Wang, Fan, Chen, Zhe-Ling, Wang, Bi-Yuan, Li, Pan, Chen, Ling, Yang, Jin
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771396/
https://ncbi.nlm.nih.gov/pubmed/26966381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S98363
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados